3410 Central Expressway
United States - Map
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. It markets HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome, as well as for the management of postherpetic neuralgia in adults in the United States. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is being studied in a Phase I clinical trial for the treatment of psoriasis and/or relapsing forms of multiple sclerosis. In addition, it is developing product candidates that have completed Phase II clinical trial, including arbaclofen placarbil, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinsons disease. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.
|Xenoport, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Ronald W. Barrett Ph.D.,
Co-Founder, Chief Exec. Officer and Director
|Mr. William G. Harris ,
Chief Financial Officer and Sr. VP of Fin.
|Mr. Vincent J. Angotti ,
Chief Operating Officer and Exec. VP
|Ms. Gianna M. Bosko ,
Chief Legal Officer, Sr. VP and Sec.
|Mr. Gregory T. Bates D.V.M.,
Sr. VP of Regulatory Affairs & Quality
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|